Elias WJ et al: A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2013;369:640.
Follett KA et al: Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 2010;362:2077.
Fox SH et al: The Movement Disorders Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S2.
Garcia-Borreguero D et al: Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study. Neurology 2010;74:1897.
Gottwald MD, Aminoff MJ: Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 2011;69:919.
Hartmann A, Worbe Y: Pharmacological treatment of Gilles de la Tourette syndrome. Neurosci Biobehav Rev 2013;37:1157.
Hauser RA et al: Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations; a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12:346.
Huster D: Wilson disease. Best Pract Res Clin Gastroenterol 2010;24:531.
Jankovic J: Medical treatment of dystonia. Mov Disord 2013;28:1001.
Kalia LV, Kalia SK, Lang AE: Disease-modifying strategies for Parkinson’s disease.
Mov Disord 2015;30:1442.
Kimber TE: An update on Tourette syndrome. Curr Neurol Neurosci Rep 2010;10:286.
Kordower JH et al: Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Mov Disord 2008;23:2303.
LeWitt PA et al: AAV2-GAD gene therapy for advanced Parkinson’s disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309.
Lorincz MT: Neurologic Wilson’s disease. Ann N Y Acad Sci 2010;1184:173.
Lyons KE, Pahwa R: Outcomes of rotigotine clinical trials: Effects on motor and nonmotor symptoms of Parkinson’s disease. Neurol Clin 2013;31(3 Suppl):S51.
Olanow CW et al: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268.
Ondo W: Essential tremor: What we can learn from current pharmacotherapy. Tremor Other Hyperkinet Mov (NY) 2016;6:356.
Palfi S et al: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: A dose escalation, open-label, phase 1/2 trial. Lancet 2014;383:1138.
PD MED Collaborative Group: Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): A large, open-label, pragmatic randomized trial. Lancet 2014;384:1196.